PharmiWeb.com - Global Pharma News & Resources

Press Releases - 2023-12-16 (4)

Date Title Company
16-Dec-2023 FDA Approves Expanded Indication for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) for the First-Line Treatment of Adult Patients With Locally Advanced or Metastatic Urothelial Cancer Businesswire